Supplementary Figure 2 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions

Giovannino Silvestri,Rossana Trotta,Lorenzo Stramucci,Justin J. Ellis,Jason G. Harb,Paolo Neviani,Shuzhen Wang,Ann-Kathrin Eisfeld,Christopher J. Walker,Bin Zhang,Klara Srutova,Carlo Gambacorti-Passerini,Gabriel Pineda,Catriona H. M. Jamieson,Fabio Stagno,Paolo Vigneri,Georgios Nteliopoulos,Philippa C. May,Alistair G. Reid,Ramiro Garzon, Denis-Claude Roy, Moutuaata M. Moutuou,Martin Guimond,Peter Hokland, Michael W. Deininger,Garrett Fitzgerald,Christopher Harman, Francesco Dazzi,Dragana Milojkovic, Jane F. Apperley, Guido Marcucci,Jianfei Qi,Katerina Machova Polakova,Ying Zou,Xiaoxuan Fan,Maria R. Baer,Bruno Calabretta,Danilo Perrotti

crossref（2023）

Cited 0|Views17

No score

Abstract

Figure S2. KEGG/GO analysis of MIR300 on PP2A-regulated signal transduction pathways. Cartoon shows the SET-dependent PP2A Inhibitory pathway in CML and the pleiotropic inhibitory effect of PP2A activation on validated and predicted MIR300 targets regulating G1/S cell cycle transition, Wnt-beta-catenin, TGFbeta, JAK-STAT, PI-3K-Akt, RAS-MAPK and Notch signaling pathways.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined

Supplementary Figure 2 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions

Supplementary Figure 2 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions